Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
27
7
2021
medline:
15
12
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
In the last decades, there has been a worldwide worrisome spread of multidrug resistant (MDR) Pseudomonas aeruginosa. Treatment of these infections is challenging, in part due to the lack of therapeutic options, and the importance of prescribing an adequate empirical treatment. Bacteraemia is one of the most severe infections, with mortality rates ranging between 20 and 40%. It is key to understand which patients are at a higher risk of MDR P. aeruginosa bloodstream infection (BSI) to better direct empirical therapies and improve overall survival. Immunocompromised patients are among the most vulnerable for the worst outcomes. Environmental exposure, integrity of the microbiota, and host immunity are the key determinants for the initial colonization and expansion on mucosal surfaces and potential invasion afterwards by MDR P. aeruginosa. Available data suggest that high colonization pressure (settings with high prevalence like intensive care units), disruption of healthy microbiota (prior use of antibiotics, in particular fluoroquinolones), immunosuppression (neutropenia) and breaking natural barriers (venous or urine catheters), are the main risk factors for MDR P. aeruginosa BSI.
Identifiants
pubmed: 34310454
doi: 10.1097/QCO.0000000000000768
pii: 00001432-202112000-00016
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
686-692Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281.
Surveillance-antimicrobial-resistance-Europe-2019. https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2019.pdf 2019.
Mensa J, Barberán J, Soriano A, et al. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa : guidelines by the Spanish Society of Chemotherapy. Rev Esp Quim 2018; 31:78–100.
Poole K. Pseudomonas aeruginosa : resistance to the max. Front Microbiol 2011; 2:65.
Recio R, Mancheño M, Viedma E, et al. Predictors of mortality in bloodstream infections caused by Pseudomonas aeruginosa and impact of antimicrobial resistance and bacterial virulence. Antimicrob Agents Chemother 2020; 64:e01759-19.
Thaden JT, Park LP, Maskarinec SA, et al. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria. Antimicrob Agents Chemother 2017; 61:e02671-16.
Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 2010; 10:441–451.
Santoro A, Franceschini E, Meschiari M, et al. Epidemiology and risk factors associated with mortality in consecutive patients with bacterial bloodstream infection: impact of MDR and XDR bacteria. Open Forum Infect Dis 2020; 7:ofaa461.
Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multidrug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect 2013; 66:401–414.
Bassetti M, Righi E, Carnelutti A. Bloodstream infections in the intensive care unit. Virulence 2016; 7:267–279.
Guillamet CV, Vazquez R, Noe J, et al. A cohort study of bacteremic pneumonia the importance of antibiotic resistance and appropriate initial therapy? Medicine (Baltimore) 2016; 95:e4708.
Kang CI, Kim SH, Kim H Bin, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745–751.
Kadri SS, Lai YL, Warner S, et al. Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2021; 21:241–251.
Britt NS, Ritchie DJ, Kollef MH, et al. Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant Pseudomonas aeruginosa sepsis. Antimicrob Agents Chemother 2018; 62:e02400-17.
Morata L, Cobos-Trigueros N, Mart́inez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2012; 56:4833–4837.
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR- P. aeruginosa ). Clin Infect Dis 2021; 72:1109–1116.
Boucher HW, Talbot GH, Benjamin DK, et al. Development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685–1694.
GLASS. Global antimicrobial resistance and use surveillance system (GLASS) report. 2020. Available at: https://www.who.int/publications/i/item/9789240027336 .
Diallo OO, Baron SA, Abat C, et al. Antibiotic resistance surveillance systems: a review. J Glob Antimicrob Resist 2020; 23:430–438.
Sader HS, Castanheira M, Duncan LR, Flamm RK. Antimicrobial susceptibility of enterobacteriaceae and Pseudomonas aeruginosa isolates from United States Medical Centers stratified by infection type: results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program. Diagn Microbiol Infect Dis 2018; 92:69–74.
Cobos-Trigueros N, Solé M, Castro P, et al. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care 2015; 19:218.
Aira A, Fehér C, Rubio E, Soriano A. The intestinal microbiota as a reservoir and a therapeutic target to fight multi-drug-resistant bacteria: a narrative review of the literature. Infect Dis Ther 2019; 8:469–482.
Tumbarello M, Repetto E, Trecarichi EM, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 2011; 139:1740–1749.
Cheong HS, Kang CI, Wi YM, et al. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia. Eur J Clin Microbiol Infect Dis 2008; 27:1219–1225.
Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: Importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306–1311.
Tam VH, Rogers CA, Chang KT, et al. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010; 54:3717–3722.
Lodise TP, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510–3515.
Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007; 30:51–59.
Bodro M, Sabé N, Tubau F, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation 2015; 99:616–622.
Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis 2000; 19:915–925.
Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501–509.
Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013; 19:474–479.
Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence 2016; 7:280–297.
Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect 2014; 68:321–331.
Ferrer M, Méndez-García C, Rojo D, et al. Antibiotic use and microbiome function. Biochem Pharmacol 2017; 134:114–126.
Raman G, Avendano EE, Chan J, et al. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2018; 7:79.
Zhao Y, Lin Q, Liu L, et al. Risk factors and outcomes of antibiotic-resistant Pseudomonas aeruginosa bloodstream infection in adult patients with acute leukemia. Clin Infect Dis 2020; 71:S386–S393.
Gudiol C, Albasanz-Puig A, Laporte-Amargós J, et al. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa . Antimicrob Agents Chemother 2020; 64:e02494-19.
Palavutitotai N, Jitmuang A, Tongsai S, et al. Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. PLoS One 2018; 13:e0193431.
Peña C, Gómez-Zorrilla S, Suarez C, et al. Extensively drug-resistant Pseudomonas aeruginosa : risk of bloodstream infection in hospitalized patients. Eur J Clin Microbiol Infect Dis 2012; 31:2791–2797.
Viasus D, Puerta-Alcalde P, Cardozo C, et al. Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clin Microbiol Infect 2020; 26:345–350.
Cassady S, Ramani GV. Right heart failure in pulmonary hypertension. Cardiol Clin 2020; 38:243–255.
Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome. J Med Microbiol 2014; 63:1679–1687.
Johnson LE, D’Agata EMC, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis 2009; 11:227–234.
Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM. Incidence rate and outcome of gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9:835–843.
Bodro M, Sabé N, Tubau F, et al. Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013; 96:843–849.
Liu T, Zhang Y, Wan Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infect Drug Resist 2018; 11:2345–2356.
Feldman N, Adler A, Molshatzki N, et al. Gastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: duration of carriage and risk factors for persistent carriage. Clin Microbiol Infect 2013; 19:E190–E196.
Lambert ML, Suetens C, Savey A, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis 2011; 11:30–38.
Babich T, Naucler P, Valik JK, et al. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study. Int J Antimicrob Agents 2020; 55:105847.
Pea C, Cabot G, Gómez-Zorrilla S, et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 2015; 60:539–548.
Goodman KE, Lessler J, Harris AD, et al. A methodological comparison of risk scores versus decision trees for predicting drug-resistant infections: a case study using extended-spectrum beta-lactamase (ESBL) bacteremia. Infect Control Hosp Epidemiol 2019; 40:400–407.